Quantcast
Last updated on April 24, 2014 at 17:35 EDT

2013 China Human Immunoglobulin (pH4) for Intravenous Injection Industry Research Report

November 12, 2013

DUBLIN, November 12, 2013 /PRNewswire/ –

Research and Markets (
http://www.researchandmarkets.com/research/3szzdk/2013_china_human) has announced the
addition of the “2013 China Human Immunoglobulin (pH4) for Intravenous Injection Industry
Research Report” [http://www.researchandmarkets.com/research/3szzdk/2013_china_human ]
report to their offering.

(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )

This 2013 research report is a professional and in-depth research report on the
Chinese Human Immunoglobulin (pH4) for Intravenous Injection industry. This report firstly
discusses the definition, classification, industry chain and other related information of
this industry.

It then reviews manufacturing technology, product specifications and summary
statistics of 25 major Chinese manufacturers 2010-2016 giving details on capacity,
production, supply, demand, shortage, selling price, cost, gross margin, production value
and market share.

In the end, this report discusses the 200K Bottles/year project feasibility analysis
and investment return analysis, and gives related research conclusions and development
trend analysis of the Chinese Human Immunoglobulin (pH4) for Intravenous Injection
industry.

Key Topics Covered:

Chapter One Human Immunoglobulin
[http://www.researchandmarkets.com/research/3szzdk/2013_china_human ] (pH4) for Intravenous
Injection Industry Overview

Chapter Two Human Immunoglobulin (pH4) for Intravenous Injection Manufacturing Process
and Cost Analysis

Chapter Three Human Immunoglobulin (pH4) for Intravenous Injection Production Supply
Sales Demand Market Status and Forecast

Chapter Four Human Immunoglobulin (pH4) for Intravenous Injection Key Manufacturers
Analysis

Chapter Five Human Immunoglobulin (pH4) for Intravenous Injection Project Investment
Feasibility Analysis

Chapter Six Human Immunoglobulin (pH4) for Intravenous Injection Industry Research
Conclusions

Companies Mentioned

– Banghe Pharmaceutical Co.,Ltd.
- Boya Biological (300294)
- CTBB
- Greencross(China)
- Guangdong Shuanglin Bio-pharmacy Co.,Ltd.
- Guangdong Weilun Biological Pharmaceutical Co.,Ltd.
- Guizhou Taibang Biological Products Co.,Ltd.
- Guizhou Zhongtai Biological S&T Co.,Ltd.
- Haikang Biological Products Co.,Ltd.
- Hualan Bio (002007)
- Hunan Unisplendour Guhan Nanyue-pharmaceutical Co.,Ltd. (000590)
- Lanzhou Institute of Biological Products Co.,Ltd.
- PAFC
- Ronsen Pharmaceutical
- Shanghai Institute of Biological Products Co.,Ltd.
- Shanghai RAAS (002252)
- Shanghai Xinxing Medicine Co.,Ltd.
- Shanxi Kangbao Biological Product Co.,Ltd.
- Shenzhen Weiwuguangming Biological Products Co.,Ltd.
- Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.
- Tonrol Pharmaceutical
- Walvax Biotechnology Co.,Ltd. (300142) (Hebei Daan)
- Wuhan Institute of Biological Products Co.,Ltd.
- Wuhan Zhongyuan Ruide Biological Products Co.,Ltd.
- Xi’an Huitian Blood Products Co.,Ltd.

For more information visit

http://www.researchandmarkets.com/research/3szzdk/2013_china_human.

        Research and Markets
        Laura Wood, Senior Manager
        press@researchandmarkets.com
        U.S. Fax: +1-646-607-1907
        Fax (outside U.S.): +353-1-481-1716
        Sector: Pharmaceuticals
         [http://www.researchandmarkets.com/categories.asp?cat_id=16&campaign_id=3szzdk ]


    Photo: 

http://photos.prnewswire.com/prnh/20130307/600769

SOURCE Research and Markets


Source: PR Newswire